Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct information

Effect of Barzolvolimab on quality measures

4 evidence topics · 4 sources

AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse
MeasureQuoted measure titleQuoted measure description
Urticaria Measure 1“Overuse: Laboratory Tests for Connective Tissue Disease”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent diagnostic testing for connective tissue disease in the absence of a history or symptoms consistent with or suggestive of a connective tissue disease.”
Urticaria Measure 2“Overuse: Laboratory Tests for Food Allergy”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for food allergies.”
Urticaria Measure 3“Overuse: Laboratory Tests for Inhalant Allergy”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for inhalant allergens.”
Urticaria Measure 4“Overuse: Laboratory Tests for Hereditary or Acquired Angioedema”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria with or without angioedema, who underwent diagnostic testing for a C1 inhibitor deficiency syndrome.”
Urticaria Measure 5“Underuse: Higher doses of Antihistamines”“The proportion of patients with chronic urticaria that is uncontrolled on monotherapy with approved doses of 2nd generation antihistamines, who are advanced as tolerated to one or more of the following: higher doses of second generation antihistamines; addition of another 2nd generation antihistamine, addition of a leukotriene antagonist, addition of an H2 blocker, or addition of a 1st generation antihistamine to be taken at bedtime.”
Product-specific effect on quality measures

No evidence found.